학술논문

Amyloid fibrils in FTLD-TDP are composed of TMEM106B and not TDP-43
Document Type
article
Source
Nature. 605(7909)
Subject
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Neurosciences
Frontotemporal Dementia (FTD)
Brain Disorders
Alzheimer's Disease
Acquired Cognitive Impairment
Prevention
Rare Diseases
Neurodegenerative
Dementia
Aging
Aetiology
2.1 Biological and endogenous factors
Neurological
Amyloid
Cryoelectron Microscopy
DNA-Binding Proteins
Frontotemporal Lobar Degeneration
Humans
Membrane Proteins
Nerve Tissue Proteins
General Science & Technology
Language
Abstract
Frontotemporal lobar degeneration (FTLD) is the third most common neurodegenerative condition after Alzheimer's and Parkinson's diseases1. FTLD typically presents in 45 to 64 year olds with behavioural changes or progressive decline of language skills2. The subtype FTLD-TDP is characterized by certain clinical symptoms and pathological neuronal inclusions with TAR DNA-binding protein (TDP-43) immunoreactivity3. Here we extracted amyloid fibrils from brains of four patients representing four of the five FTLD-TDP subclasses, and determined their structures by cryo-electron microscopy. Unexpectedly, all amyloid fibrils examined were composed of a 135-residue carboxy-terminal fragment of transmembrane protein 106B (TMEM106B), a lysosomal membrane protein previously implicated as a genetic risk factor for FTLD-TDP4. In addition to TMEM106B fibrils, we detected abundant non-fibrillar aggregated TDP-43 by immunogold labelling. Our observations confirm that FTLD-TDP is associated with amyloid fibrils, and that the fibrils are formed by TMEM106B rather than TDP-43.